What is Phase Focus?
Phase Focus Limited is a specialized technology firm at the intersection of biology and advanced imaging. The company is best known for its Livecyte platform, which leverages patented quantitative phase imaging to provide high-fidelity, automated tracking and analysis of live cells. By enabling researchers to observe complex biological processes—such as cell motility, proliferation, and wound healing—without the need for invasive labeling, Phase Focus provides a critical tool for oncology and broader life sciences research.
The company's market position is defined by its commitment to innovation, having received multiple accolades for its unique approach to characterizing live cell behavior. By offering versatile assays and robust technical support, Phase Focus serves as a vital partner for academic and commercial institutions seeking to enhance the precision and reliability of their biological research outcomes.
How much funding has Phase Focus raised?
Phase Focus has raised a total of $6.8M across 3 funding rounds:
Unspecified
$1.2M
Unspecified
$571K
Unspecified
$5M
Unspecified (2008): $1.2M with participation from Spirit Capital Partners and Fusion IP
Unspecified (2009): $571K led by Maven Capital Partners UK, Yorkshire association of business angels, and South Yorkshire Investment fund
Unspecified (2012): $5M supported by Ombu Group
Key Investors in Phase Focus
Ombu Group
Ombu Group invests in and provides management support to advanced environmental technology companies, focusing on a small number of businesses to ensure substantial backing.
Maven Capital Partners UK
Maven Capital Partners UK LLP is a prominent firm operating in the venture capital and private equity industry, known for supporting high-growth potential enterprises.
Yorkshire association of business angels
The Yorkshire Association of Business Angels is a regional forum that bridges the gap in the equity market by connecting experienced investors with innovative entrepreneurs.
What's next for Phase Focus?
With the recent major strategic investment of $5M, Phase Focus is poised to transition into a new phase of commercial scaling and product expansion. The company's strategic roadmap likely involves deepening its penetration into the global oncology research market and enhancing the computational capabilities of the Livecyte platform. As the firm moves beyond its initial development stages, the focus will shift toward optimizing operational efficiency and expanding its footprint in international life sciences markets.
The backing from experienced institutional investors provides not only the necessary liquidity for growth but also the strategic oversight required to navigate the complexities of the biotechnology sector. Future efforts will likely prioritize the integration of artificial intelligence into their imaging workflows, further cementing their status as a leader in non-invasive, high-throughput cell analysis.
